Current Report · Items 7.01, 9.01 · 8-K

Silexion Therapeutics Corp

SLXNNASDAQEQUITYCurrent

Regulation FD Disclosure

Filed Sep 28, 2026Accepted Sep 28, 2026, 8:46 AM EDTCIK 2022416Accession 0001178913-26-004628

Company context

We are a clinical-stage biotechnology company developing, through our subsidiaries, RNA interference (RNAi) therapies for cancers driven by mutations in the Kirsten rat sarcoma viral oncogene homolog (“KRAS”). Our approach targets a significant unmet medical need, as treatment innovation for KRAS-driven cancers has historically lagged despite KRAS being one of the most common oncogenic drivers across solid tumors. In pancreatic cancer, for example, approximately 92% of patients have this mutated oncogene. While multiple pharmaceutical companies are pursuing strategies to inhibit KRAS and thereby limit its downstream signaling, our approach is differentiated by targeting the root cause of oncogenic signaling; our lead product candidate, SIL204, is a second-generation siRNA therapy that is engineered to suppress the KRAS oncogene itself, preventing the production of the oncogenic protein. We utilize an integrated treatment approach that combines administering SIL204 both directly into the tumor and systemically via subcutaneous injection, in combination with standard-of-care chemotherapy. In a previous Phase 2 clinical trial with our first-generation siRNA, the combination of siRNA and standard-of-care chemotherapy demonstrated an overall survival benefit compared to standard-of-care chemotherapy alone. Building on preclinical advancements and regimen optimization, we believe SIL204 has the potential to further improve clinical outcomes.

Current securities

SLXNNASDAQ · EQUITY · Current SLXNWNASDAQ · WARRANT · Current

Recent company filings

Registered securities in this filing

Silexion Therapeutics Corp · 8-K · Filed 2026-09-28

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Ordinary Shares, par value $0.135 per share

Symbol: SLXN
Exchange: NASDAQ
Classification: COMMON
Status: Current

Filing context

Context: From2026-09-282026-09-28_us-gaap_CommonStockMember

Dimensions: us-gaap:StatementClassOfStockAxis

Warrants exercisable for Ordinary Shares at an exercise price of $15,525.00 per share

Symbol: SLXNW
Exchange: NASDAQ
Classification: WARRANT
Status: Current

Filing context

Context: From2026-09-282026-09-28_custom_WarrantsExercisableForOrdinarySharesMember

Dimensions: us-gaap:StatementClassOfStockAxis

Accession 000117891326004628 · 2 registered-security cover members

Read the exact SEC filing ↗

Disclosure sections

Items 7.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 7.01Item 7.01 - Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On September 28, 2026, Silexion Therapeutics Corp issued a press release entitled “Silexion Therapeutics Reports Positive Preclinical Findings for SIL204, Demonstrating Key Mechanism for Endogenous Systemic Uptake in KRAS-Driven Cancers”. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this “Form 8-K”) and is incorporated herein by reference. The information in this Item 7.01 of Form 8-K, including the information in the press release furnished pursuant to this Item 7.01, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. Furthermore, the information in this Item 7.01, including the information in the press release, shall not be deemed to be incorporated by reference in the filings of the registrant under the Securities Act of 1933, as amended.